Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback